drugset / Trial / NCT00239044

An Open Label Study to Evaluate the Tolerability and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Combination With Cyclosporine Microemulsion (CsA-ME) in Maintenance Renal Transplant Recipients

NCT00239044

Phase 3 Completed 40 enrolled Novartis Pharmaceuticals
Non-randomizedSingle-groupOpen-labelPrevention

Summary

To evaluate whether maintenance renal transplant patients on micophenolate mofetil (MMF) can be safely converted to EC-MPS, based on adverse events and acute rejection within 6 months after switching from MMF to a EC-MPS regimen.

Timeline

Start
2002-12
Primary completion
2005-07
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Mycophenolate Sodium Unknown